An outbreak of e-cigarette, or vaping, associated lung injury (EVALI) was noted in the USA starting in March of 2019 [1]. Although there have been prior reports of various lung… Click to show full abstract
An outbreak of e-cigarette, or vaping, associated lung injury (EVALI) was noted in the USA starting in March of 2019 [1]. Although there have been prior reports of various lung diseases associated with e-cigarette use since they first came on the market in 2011 [2], the outbreak this summer was remarkable in the large number of patients affected (2409 reported hospitalised with 52 deaths as of 13 December, 2019 in the USA alone [1]) and the severity of lung injury. Although e-cigarette use is quite common in Europe [3], to date no cases of EVALI that developed in Europe have been reported. Questions regarding the geographic distribution of EVALI in the context of the global distribution and use of e-cigarettes have been raised. The first case of e-cigarette, or vaping, associated lung injury (EVALI) diagnosed and treated in Europe reminds us to remain vigilant for this diagnosis, and importantly, that we are still learning about the full spectrum of risks of e-cigarette use http://bit.ly/2TauItr
               
Click one of the above tabs to view related content.